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Clopidogrel Alone is Not Sufﬁcient to Prevent Stent Thrombosis in Diabetic
Patients Requiring Warfarin.
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Background: Triple therapy with ASA, clopidogrel and warfarin (ACW) is associated
with increased bleeding, but there is no data that evaluates whether clopidogrel and
warfarin without ASA (CW) is sufﬁcient in preventing stent thrombosis (ST). This
study tested whether omitting ASA in patients on warfarin and clopidogrel who
received either BMS or DES was effective and decreased bleeding.
Methods: 396 consecutive patients undergoing PCI at a single urban center were
enrolled. All were discharged on clopidogrel 75 mg. Patients already on warfarin were
continued. The choice to start ASA 325 mg was at the discretion of the cardiologist.
Patients were followed for at least 1 year. The drug regimen selected was maintained
for at least 1 month after BMS and 1 year after DES. Primary endpoints were all-cause
mortality, MI, stroke, ST, target vessel revascularization. Secondary endpoints
included bleeding events.
Results: Baseline characteristics are shown. The indication for warfarin was atrial
ﬁbrillation in 74% and mechanical valve 12%; the remainder included venous
thromboembolism, severe systolic dysfunction, and the presence of LV thrombus.
Multivariate analyses showed diabetes to be a statistically signiﬁcant determinant
of ST.P
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warfarin. ACW reduces the incidence of ST and lowers all-cause mortality but is
associated with increased bleeding risk. Importantly, CW prevents ST in non-diabetic
patients who require warfarin with less bleeding events, and may be the preferred
antithrombotic therapy in this subgroup.
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Background: Interindividual variability in platelet response to thienopyridines has
been implicated as a reason making platelet function testing (PFT) unsuitable for
diagnosing drug noncompliance. Because of variability in platelet response to tica-
grelor might be more limited, we aimed to assess PFT usefulness to detect noncom-
pliance to ticagrelor.
Methods: Over 15 months period all patients who were discharged on ticagrelor 90
mg bid maintenance dose were invited for clinical follow-up and PFT at 1 month post
discharge. We studied platelet reactivity (PR) in 211 patients who were self-reported
as compliant to therapy using the VerifyNow P2Y12 function assay (in PRU).
Results: There were 175(82.9 %) men, with a median (Q1-Q3) age of 59.0(51.0-69.0)
years. PR frequency distribution is depicted in Figure. Apart from 3 patients, PR
varied within a narrow range with quartile coefﬁcient of dispersion ¼ 0.65. The 3
patients were invited for ticagrelor administration under medical surveillance and re-
PFT. Case 1 and 2 (in red) admitted not taking regularly ticagrelor at 1 month visit and
at re-PTF had 5 PRU and 88 PRU, respectively, supporting the diagnosis of drug
noncompliance. Case 3 was receiving phenytoin, whose co-administration may lead to
a decrease in exposure and efﬁcacy of ticagrelor and exhibited 149 PRU at re-PTF.
Conclusions: In patients under chronic ticagrelor treatment and in the absence of co-
medication possibly leading to a decrease in its efﬁcacy, an increased PR should
strongly raise the suspicion of noncompliance. PFT may be a useful tool for
noncompliance to ticagrelor detection.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-160
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Background: P2Y12 inhibitor switching has appeared in clinical practice as
a consequence of prasugrel and ticagrelor availability, apart from clopidogrel, for use
in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary
intervention (PCI). In-hospital P2Y12 inhibitor switching has not been adequately
studied.
Methods: In the context of the GReek AntiPlatelet REgistry (GRAPE) we assessed
the prevalence, predictive factors and short-term outcome of in-hospital P2Y12
inhibior switching inACS patients undergoing PCI.
Results: We recruited 1434 patients. Switching occurred in 526(36.7%) patients of
which in the form of clopidogrel to a novel agent, novel agent to clopidogrel and
between prasugrel and ticagrelor in 480(91.2%), 26(5.0%) and 20(3.8%) patients,
respectively. Age75 years, presentation to non PCI-capable hospital, history of
stroke/transient ischemic attack, asthma/chronic obstructive pulmonary disease and
regional trends emerged as predictive factors of switching to a novel agent. At
combined in-hospital and one-month follow-up upgrading to a novel agent did not
confer any ischemic or bleeding difference than novel agent constant administration,
while it was accompanied by higher Bleeding Academic Research Consortium
(BARC) type 1 (21.9%) and BARC any type (28.3%) bleeding events compared to
only clopidogrel administration (8.7% and 11.9%, respectively), p<0.001 for both in
propensity matched pairs analysis.
Conclusions: In a real-life experience with contemporary antiplatelet treatment in
ACS patients undergoing PCI, in-hospital switching represents common clinical
practice. Clinical factors and regional practice differences seem to affect this strategy's
choice, while P2Y12 inhibitor upgrade may be associated with higher than clopidogrel
risk of bleeding.
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Background: Ticagrelor (TICA) was more efﬁcient than clopidogrel (CLO) in pre-
venting cardiovascular events after Acute Coronary Syndrome (ACS) in the PLATO
trial. However, it was associated with a higher incidence of non-procedural bleedings.
A TICA loading dose could be unnecessary in patients with ongoing CLO therapy.
Aim of the present study was to verify whether the administration of a loading dose
leads to an additional inhibition of platelet aggregation during the switch from
ongoing CLO to TICA therapy.
Methods: Fifty patients with ACS and on CLO treatment were randomly assigned to
a starting dose of TICA of 90mg or 180mg, on top of aspirin treatment. Platelet (PLT)
aggregation was measured using Multiple Electrode Aggregometry (MEA) at 0, 2, 6,acts/POSTER/Antiplatelets and Antithrombins B51
